Suppr超能文献

Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.

作者信息

Mura C, Gerard N, Vincent-Viry M, Galteau M M, Jacqz-Aigrain E, Krishnamoorthy R

机构信息

INSERM U120, Hôpital Robert Debre, Paris, France.

出版信息

Br J Clin Pharmacol. 1993 Feb;35(2):161-5. doi: 10.1111/j.1365-2125.1993.tb05681.x.

Abstract
  1. Cytochrome P450 debrisoquine (CYP2D6) activity is polymorphic and under genetic control. Most Caucasians are extensive metabolizers, but 5%-10% are poor metabolizers. 2. Restriction fragment length polymorphism analysis of the CYP2D6 locus identifies a 29kb XbaI fragment, either normal (D6-wt) or mutated, and three mutated XbaI alleles (44kb, 11.5kb and 16 + 9kb). The 44kb allele was initially considered as a poor metabolizer allele owing to a D6-B mutation, but cases of 44kb allele not carrying the D6-B, and therefore potentially functional, have been found. The degree of molecular heterogeneity of this allele was investigated by phenotype and genotype analysis of families. 3. Thirty-one French Caucasian families, representing 117 individuals, possessing at least one 44kb allele in each family were selected. Phenotypes were determined using dextromethorphan, and the XbaI, NcoI and BamH1 RFLPs of 42 independent chromosomes were analyzed. 4. 80% of the XbaI 44kb alleles carried the CYP2D6-B mutation and had an additional NcoI fragment (12.5kb or 4.8kb). The remaining 20% did not carry the CYP2D6-B or A mutations and had no extra NcoI fragment. 5. Information on three families demonstrated that 44kb alleles not carrying the CYP2D6-B mutation were associated with the extensive metabolizer phenotype. 6. We conclude that a substantial percentage of XbaI 44kb alleles is associated with a functional CYP2D gene, and therefore, that the XbaI 44kb allele is not consistently a poor metaboliser allele.
摘要

相似文献

1
Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
Br J Clin Pharmacol. 1993 Feb;35(2):161-5. doi: 10.1111/j.1365-2125.1993.tb05681.x.
3
Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Pharmacogenetics. 1995 Aug;5(4):215-23. doi: 10.1097/00008571-199508000-00005.
6
Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Carcinogenesis. 1990 Sep;11(9):1527-30. doi: 10.1093/carcin/11.9.1527.
8
CYP2D6 genotype determination in the Danish population.
Eur J Clin Pharmacol. 1994;47(3):221-5. doi: 10.1007/BF02570501.
9
Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
Pharmacogenetics. 1991 Dec;1(3):161-4. doi: 10.1097/00008571-199112000-00006.

引用本文的文献

本文引用的文献

2
Genetically determined oxidation capacity and the disposition of debrisoquine.
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
4
P450 genes: structure, evolution, and regulation.
Annu Rev Biochem. 1987;56:945-93. doi: 10.1146/annurev.bi.56.070187.004501.
5
Phenotyping polymorphic drug metabolism in the French Caucasian population.
Eur J Clin Pharmacol. 1988;35(2):167-71. doi: 10.1007/BF00609247.
8
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Eur J Clin Pharmacol. 1989;36(6):537-47. doi: 10.1007/BF00637732.
10
The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
Pharmacol Ther. 1990;46(3):377-94. doi: 10.1016/0163-7258(90)90025-w.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验